logo
Twitter
Discord
Email
logo
EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

NASDAQ•EYPT
CEO: Dr. Jay S. Duker M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2005-01-27
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Contact Information
480 Pleasant Street, Suite A-210, Watertown, MA, 02472, United States
617-926-5000
eyepointpharma.com
Market Cap
$1.26B
P/E (TTM)
-5.2
37
Dividend Yield
--
52W High
$19.11
52W Low
$3.91
52W Range
74%
Rank67Top 97.6%
1.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$966.00K-90.82%
4-Quarter Trend

EPS

-$0.85+57.41%
4-Quarter Trend

FCF

-$60.15M+48.15%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

R&D Investment Surge R&D expenses increased 81% to $161.8M for nine months, driven by ongoing DURAVYUTM Phase 3 clinical trials.
Royalty Income Spike Royalty income surged 830% to $12.9M due to ANI buyout of the perpetual SWK royalty obligation.
Strong Cash Position Cash and marketable securities totaled $204.0M at September 30, 2025, supported by recent equity financing.
Equity Financing Closed Secured $162.1M net proceeds from October 2025 underwritten public offering to fund future operations.

Risk Factors

Deepening Operating Losses Net loss widened 84% to $164.4M for nine months, reflecting substantial investment in pipeline development.
DOJ Investigation Accrual Recorded $4.7M accrual for potential DOJ settlement regarding DEXYCU® sales and promotional practices.
Declining Core Revenue Product sales dropped 46% to $1.3M (9M) following the automatic termination of the ANI supply agreement.
Funding Dependency Risk Operations rely on future capital raises; failure to obtain adequate financing could curtail development programs.

Outlook

Extended Runway Current cash plus $162.1M financing extends operational runway into Q4 2027, beyond key data readouts.
DURAVYUTM Trials Progress Phase 3 wet AMD trials completed enrollment; pivotal DME trial dosing expected in Q1 2026.
Continued High R&D Spend Anticipate R&D expenses remaining at similar high levels due to ongoing Phase 3 trials and manufacturing scale-up.
Regulatory Approval Focus Future success hinges on timing and outcome of regulatory interactions and approvals for DURAVYUTM indications.

Peer Comparison

Revenue (TTM)

Maravai LifeSciences Holdings, Inc.MRVI
$192.28M
-30.6%
AnaptysBio, Inc.ANAB
$169.47M
+196.4%
Xencor, Inc.XNCR
$167.36M
+64.5%

Gross Margin (Latest Quarter)

Xencor, Inc.XNCR
100.0%
+17.2pp
Tango Therapeutics, Inc.TNGX
99.0%
-1.0pp
Phathom Pharmaceuticals, Inc.PHAT
87.5%
+1.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PGEN$1.43B-5.7-3342.6%57.3%
ANAB$1.32B-16.3-1101.2%98.1%
TNGX$1.29B-12.9-60.8%16.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-56.3%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 4, 2026
|
EPS:-$0.78
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $966.00K-90.8%
    |
    EPS: $-0.85+57.4%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $5.33M-43.7%
    |
    EPS: $-0.85+46.6%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $24.45M+109.3%
    |
    EPS: $-0.65+18.2%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 6, 2025|
    Revenue: $43.27M-6.0%
    |
    EPS: $-2.32-27.5%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $10.52M-30.8%
    |
    EPS: $-0.54+63.6%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $9.48M+4.1%
    |
    EPS: $-0.58-4.9%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $11.68M+52.1%
    |
    EPS: $-0.55-5.2%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 8, 2024|
    Revenue: $46.02M+11.1%
    |
    EPS: $-1.82+33.6%
    Miss